Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test
Open Access
- 15 July 2014
- journal article
- review article
- Published by Wiley in Molecular Oncology
- Vol. 9 (5) , 940-950
Abstract
The new age of Precision Cancer Medicine, with specific biomarkers being used to direct targeted agents, generally concerns only a subset of patients within a certain histopathologically defined tumor type. This paradigm is challenged by the need to perform widespread molecular screening in certified laboratories, with results available to clinicians within reasonable timeframe. Tumor heterogeneity and clonal evolution must be considered in the decision making process. Adaptive and innovative clinical trial designs exploring predictive algorithms and reconsideration of traditional efficacy endpoints are required to rapidly translate scientific discoveries into patient care. Furthermore, international collaboration in cancer research and open discussions on the availability of investigational agents will likely redefine the drug development and approval process in the coming years.Keywords
This publication has 32 references indexed in Scilit:
- Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial DataEuropean Urology, 2014
- Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)The Lancet Oncology, 2014
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2013
- Phase III Trials of Targeted Anticancer Therapies: Redesigning the ConceptClinical Cancer Research, 2013
- Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2013
- Genomic Medicine Frontier in Human Solid Tumors: Prospects and ChallengesJournal of Clinical Oncology, 2013
- Implementing personalized cancer genomics in clinical trialsNature Reviews Drug Discovery, 2013
- Tumor Assessment Criteria in Phase I Trials: Beyond RECISTJournal of Clinical Oncology, 2013
- Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trialInternational Journal of Cancer, 2012
- The developing cancer stem-cell model: clinical challenges and opportunitiesThe Lancet Oncology, 2012